Bacterial Pathogenesis and Immunity Group

Funding

Our funders include Action Medical Research, BMA, BBSRC, Cystic Fibrosis Trust, JPIAMR, Horizon 2020 European Commission, Innovate UK, Meningitis now, MRC, NIH and Wellcome Trust.

FunderProject
Cystic Fibrosis Trust. 2021-2025 An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis
Horizon 2020 Research and Innovation Framework Programme. 2021-2025 Inhalable Aerosol Light Source for Controlling Drug Resistant Bacterial Lung Infections

BBSRC Project Grant. 2021 – 2024   Does CRISPR-Cas immunity limit the effectiveness of phage therapy? 
NIH SF 424 (R&R) Grant. 2021 - 2023   Biofilm disrupting antibody to treat respiratory infections  
BBSRC Project Grant. 2021-2022   In Vitro Organ Imaging Device (IV-OID) with integrated Biosensing and Real-Time Imaging Capability: Proof-of-Principle using a Human Placental Model 
Innovate UK. 2020-2022 SPOR-COV: Prophylaxis of COVID-19 using Innate Immunity 
MRC Programme Grant. 2017–2022   The role of immune tolerance and regulation in pneumococcal carriage and invasive disease.
British Medical Association Foundation. 2019-2022 Immune profiling and high-throughput taxonomic analysis of the nasopharyngeal microbiota of infants presenting with acute viral respiratory tract infection

Bacterial Pathogenesis and Immunity Group funders

Back to: Institute of Infection, Veterinary and Ecological Sciences